Ketamine in Bipolar Disorder: A Review
Alina Wilkowska, Łukasz P. Szałach, Wiesław Jerzy Cubała
Neuropsychiatric Disease and Treatment November 1, 2020 DOI: 10.2147/ndt.s282208 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Topics | Depression Ketamine Esketamine |
| Keywords | Bipolar disorder Depression economics Suicide rates Lithium medication Poison control Cognition Suicide prevention Medical emergency |
| Citations | 31 |
| Key points | Argues that ketamine might be a promising treatment for bipolar disorder due to its rapid antidepressive and antisuicidal effects. |
Abstract
Abstract: Bipolar disorder (BD) is a psychiatric illness associated with high morbidity, mortality and suicide rate. It has neuroprogressive course and a high rate of treatment resistance. Hence, there is an unquestionable need for new BD treatment strategies. Ketamine appears to have rapid antidepressive and antisuicidal effects. Since most of the available studies concern unipolar depression, here we present a novel insight arguing that ketamine might be a promising treatment for bipolar disorder. Keywords: ketamine, bipolar disorder, staging, neuroprogression, treatment resistance
Comparable studies
Other theoretical and historical papers on ketamine for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| An Integrative Approach to Ketamine Therapy May Enhance Multiple Dimensions of Efficacy: Improving Therapeutic Outcomes With Treatment Resistant Depression. | 2021 | Theoretical or philosophical paper | |
| Arketamine for cognitive impairment in psychiatric disorders | 2023 | Theoretical or philosophical paper | |
| The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression | 2023 | Theoretical or philosophical paper | |
| Rethinking the role of TRKB in the action of antidepressants and psychedelics. | 2024 | Theoretical or philosophical paper | |
| Off-label use of ketamine for treatment-resistant depression in clinical practice: European perspective. | 2019 | Theoretical or philosophical paper |
Citations in the library
Cited by 13
- Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study Neuropsychiatric Disease and Treatment August 1, 2021
- Gut Microbiota in Depression: A Focus on Ketamine Frontiers in Behavioral Neuroscience June 23, 2021
- Expert Opinion on Psychedelic-Assisted Psychotherapy for People with Psychotic Symptoms Research Square January 25, 2022
- Adjunctive music improves the tolerability of intravenous ketamine for bipolar depression International Clinical Psychopharmacology April 23, 2021
- Intranasal esketamine use in bipolar disorder: A case report Mental Health Clinician July 1, 2021
and 8 more in the library
Cites 32
- NMDAR inhibition-independent antidepressant actions of ketamine metabolites Nature April 24, 2016
- A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression Archives of General Psychiatry August 1, 2010
- The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis American Journal of Psychiatry October 3, 2017
- R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects Translational Psychiatry September 1, 2015
- Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder The Journal of Clinical Psychiatry July 13, 2010
and 27 more in the library